Skip to main content
Pharmanutra logo

Pharmanutra — Investor Relations & Filings

Ticker · PHN ISIN · IT0005274094 LEI · 815600F8217BC7733697 XMIL Manufacturing
Open in API
Filings indexed 601 across all filing types
Latest filing 2018-12-20 Regulatory Filings
Country IT Italy
Listing XMIL PHN

About Pharmanutra

http://www.pharmanutra.it

PharmaNutra is a company operating in the pharmaceutical and nutraceutical sectors, focused on the development and distribution of nutritional supplements and medical devices. Grounded in scientific research, the company creates innovative solutions for health and wellness. Its core activities center on addressing nutritional deficiencies, particularly iron, through proprietary functional ingredients and technologies. The product portfolio also extends to supporting muscle and joint health, sports nutrition, and applications across various therapeutic areas, including gynecology, orthopedics, hematology, and gastroenterology. The company emphasizes the development of effective and safe products supported by clinical evidence.

Recent filings

Filing Released Lang Actions
CS PharmaNutra Distribuzione Cetilar in Thailandia
Regulatory Filings Classification · 1% confidence The document is a formal communication from Pharmanutra S.p.A. dated December 20, 2018, identified as 'Informazione Regolamentata' (Regulated Information) from AIM Italia. The subject ('Oggetto') is the signing of a distribution agreement for the Cetilar® line in Thailand. This type of announcement, detailing a significant business development (international expansion/partnership), is typically classified as a general regulatory announcement or a specific business update. Since it is not a full financial report (10-K, IR), an earnings release (ER), a management discussion (MDA), or a specific transaction like a share buyback (POS) or director dealing (DIRS), it fits best under the general category for significant, non-standard regulatory disclosures. Given the context of a major international business agreement announcement, and lacking a more specific category like M&A (TAR), it is classified as a Regulatory Filing (RNS) as a broad category for significant, non-standard disclosures, or potentially a Capital/Financing Update (CAP) if the expansion was framed as capital deployment, but RNS is safer for general business news filings. However, reviewing the definitions, this is a material business event announcement. It is not a proxy statement (PSI), dividend notice (DIV), or audit report (AR). It is a material business development announcement. Since it is a formal, regulated communication about a strategic business move (international distribution agreement), and not a specific financial report, RNS (Regulatory Filings - general fallback) is appropriate, although some systems might use a specific 'Material Event Disclosure' code if available. Based on the provided list, RNS is the most suitable general regulatory disclosure category.
2018-12-20 Italian
CS PharmaNutra nella top 10 di AIM Italia
Regulatory Filings Classification · 1% confidence The document is titled 'Informazione Regolamentata' (Regulated Information) and is dated December 14, 2018. The subject ('Oggetto') is 'CS PharmaNutra nella top 10 di AIM Italia' (PharmaNutra in the top 10 of AIM Italia). The content discusses the company's positive performance and capitalization ranking based on an article in Milano Finanza. This is a general announcement regarding company news and performance highlights, not a full financial report (like 10-K or IR), a transcript (CT), or a specific regulatory filing like insider trading (DIRS) or dividend notice (DIV). Since it is a general, non-specific announcement of positive news that doesn't fit the other specific categories (like ER, which is usually quarterly results), it best fits the general 'Regulatory Filings' fallback category (RNS) for miscellaneous regulatory communications, or potentially an Earnings Release (ER) if it were summarizing results, but here it is summarizing a third-party ranking. Given the nature of the announcement (a press release style communication about market performance), RNS is the most appropriate general regulatory announcement category.
2018-12-14 Italian
CS Pharmanutra nuove applicazioni per il ferro sucrosomiale
Regulatory Filings Classification · 1% confidence The document is a formal communication identified by the header "Informazione Regolamentata n. 20106-23-2018" and dated December 10, 2018, originating from the AIM-Italia market. The subject ("Oggetto") is "CS Pharmanutra nuove applicazioni per il ferro sucrosomiale" (Pharmanutra press release new applications for sucrosomial iron). The content details the publication of a scientific study confirming the efficacy of their patented iron technology in patients with Inflammatory Bowel Disease (IBD). This is a press release announcing positive scientific/clinical findings, which is a form of corporate communication intended for investors and the public. It is not a full Annual Report (10-K), an Interim Report (IR), or a specific regulatory filing like a Director's Dealing (DIRS) or Capital Change (SHA). Since it is a formal press release announcing business/scientific developments, it fits best under the general category of Regulatory Filings (RNS) as a catch-all for official announcements that aren't covered by more specific codes like ER or CT, or it could be interpreted as an Investor Presentation (IP) if it were a slide deck, but given the format and context of an Italian "Comunicato Stampa" (CS), RNS is the most appropriate general regulatory announcement code.
2018-12-10 Italian
C.S. Pharmanutra aderisce a Farmindustria
Regulatory Filings Classification · 1% confidence The document is an official communication from Pharmanutra S.p.A. dated December 4, 2018, identified by the header 'Informazione Regolamentata' (Regulated Information) and the type 'REGEM'. The subject ('Oggetto') is 'C.S. Pharmanutra aderisce a Farmindustria' (Pharmanutra joins Farmindustria). This is an announcement regarding the company joining an industry association (Farmindustria). This type of corporate news, which is not a financial report (like 10-K, IR, ER), a management change (MANG), or a shareholder vote result (DVA), fits best under the general category for regulatory announcements that do not have a more specific code. Since it is a formal, regulated announcement that doesn't fit the other specific categories, it defaults to the general regulatory filing category.
2018-12-04 Italian
cs pharmanutra vendite all'estero
Earnings Release Classification · 1% confidence The document is an official communication ('Informazione Regolamentata') from Pharmanutra S.p.A. dated November 21, 2018. The subject ('Oggetto') is 'cs pharmanutra vendite all'estero' (Pharmanutra press release foreign sales). The content discusses commercial results for the first 9 months of 2018, highlighting international sales growth and new distribution partnerships. This structure—a brief announcement summarizing key operational and financial highlights for a specific period (9 months)—is characteristic of an Earnings Release (ER), which typically precedes or is the primary announcement of quarterly/periodical results. It is not a full Annual Report (10-K) or a comprehensive Interim Report (IR), as it focuses on sales trends and partnerships rather than detailed financial statements. Since it announces key results for a period shorter than a year (9 months), it fits best under the Earnings Release category, which covers initial announcements of periodical financial results. 9M 2018
2018-11-21 Italian
Pubblicati ulteriori studi sul ferro sucrosomiale
Report Publication Announcement Classification · 1% confidence The document is an official regulatory announcement from an Italian company (Pharmanutra S.p.A.) dated November 5, 2018, identified by the header "Informazione Regolamentata n. 20106-20-2018". The subject ("Oggetto") is "Pubblicati ulteriori studi sul ferro sucrosomiale" (Further studies published on sucrosomial iron). The text explicitly states that new scientific studies regarding their product have been published and provides links to download the full studies, concluding with a statement about the company's ongoing research. This structure—an official notification announcing the publication of research/data—fits the definition of a Report Publication Announcement (RPA), as it is announcing the availability of external reports (the scientific studies) rather than being the full report itself (like an ER or IR). It is not a general regulatory filing (RNS) because a more specific category (RPA) applies.
2018-11-05 Italian

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.